CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
In this phase II advanced melanoma study, all patients will receive treatment with nivolumab/ipilimumab plus cabozantinib for a 12 week indu...
Phase 2
Baltimore, Maryland, United States and 2 other locations
alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who ...
Phase 3
Bethesda, Maryland, United States and 53 other locations
(PK) similarity and efficacy, safety, and immunogenicity of ABP 206 compared with OPDIVO® (nivolumab) in subjects with resected advanced melanoma...
Phase 3
Baltimore, Maryland, United States and 110 other locations
cell death protein-1 (PD-1) inhibitor, in patients with metastatic melanomas or advanced solid tumors. Our hypothesis is that restoration of...
Phase 1, Phase 2
Washington, District of Columbia, United States and 20 other locations
assess the efficacy, safety, and immunogenicity of ABP 206 compared with Nivolumab in Subjects with Treatment-Naïve Unresectable or Metastatic Melanoma...
Phase 3
Baltimore, Maryland, United States and 144 other locations
of ceralasertib, when administered as monotherapy and in combination with durvalumab in participants with unresectable or advanced melanoma ...
Phase 2
Lutherville-Timonium, Maryland, United States and 65 other locations
and pharmacokinetic profiles of botensilimab as monotherapy and in combination with balstilimab in participants with advanced cutaneous melanoma...
Phase 2
Washington, District of Columbia, United States and 48 other locations
patients with unresectable Stage III or IV melanoma. The contributions of BNT111 and cemiplimab will be delineated in single agent...
Phase 2
Fairfax, Virginia, United States and 52 other locations
to assess nivolumab plus relatlimab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma...
Phase 3
Washington, District of Columbia, United States and 171 other locations
treatment of adult subjects with completely treated high-risk ocular melanoma, as defined in eligibility criteria, without evidence of metas...
Phase 2
Washington, District of Columbia, United States and 5 other locations
Clinical trials
Research sites
Resources
Legal